Us Stem Cell Stock Analysis
| USRM Stock | USD 0.0001 0.00 0.00% |
US Stem Cell holds a debt-to-equity ratio of -1.03. US Stem's financial risk is the risk to US Stem stockholders that is caused by an increase in debt.
Given that US Stem's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which US Stem is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of US Stem to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, US Stem is said to be less leveraged. If creditors hold a majority of US Stem's assets, the Company is said to be highly leveraged.
US Stem Cell is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of US Stem pink sheet analysis is to determine its intrinsic value, which is an estimate of what US Stem Cell is worth, separate from its market price. There are two main types of US Stem's stock analysis: fundamental analysis and technical analysis.
The US Stem pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
USRM |
USRM Pink Sheet Analysis Notes
The company recorded a loss per share of 0.01. US Stem Cell had not issued any dividends in recent years. The entity had 1:1000 split on the 4th of November 2015. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida. US Stem operates under Biotechnology classification in the United States and is traded on OTC Exchange.The quote for US Stem Cell is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more information please call Michael Tomas at 954 835 1500 or visit https://www.us-stemcell.com.US Stem Cell Investment Alerts
| US Stem Cell generated a negative expected return over the last 90 days | |
| US Stem Cell has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 3.07 M. Net Loss for the year was (3.84 M) with profit before overhead, payroll, taxes, and interest of 148.72 K. | |
| US Stem Cell currently holds about 10.33 K in cash with (1.21 M) of positive cash flow from operations. |
USRM Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.05 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate US Stem's market, we take the total number of its shares issued and multiply it by US Stem's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
Concerning fundamental indicators, the technical analysis model makes it possible for you to check potential technical drivers of US Stem Cell, as well as the relationship between them.US Stem Cell Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
US Stem Outstanding Bonds
US Stem issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. US Stem Cell uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most USRM bonds can be classified according to their maturity, which is the date when US Stem Cell has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| UBS 4125 15 APR 26 Corp BondUS90351DAF42 | View | |
| UBS 4253 23 MAR 28 Corp BondUS90352JAC71 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US90353TAK60 Corp BondUS90353TAK60 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
US Stem Cell Debt to Cash Allocation
Many companies such as US Stem, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
US Stem Cell currently holds 722.06 K in liabilities. Debt can assist US Stem until it has trouble settling it off, either with new capital or with free cash flow. So, US Stem's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like US Stem Cell sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for USRM to invest in growth at high rates of return. When we think about US Stem's use of debt, we should always consider it together with cash and equity.US Stem Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the US Stem's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of US Stem, which in turn will lower the firm's financial flexibility.US Stem Corporate Bonds Issued
About USRM Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how US Stem prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling USRM shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as US Stem. By using and applying USRM Pink Sheet analysis, traders can create a robust methodology for identifying USRM entry and exit points for their positions.
Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida. US Stem operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding US Stem to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Bollinger Bands Now
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon |
| All Next | Launch Module |
Other Information on Investing in USRM Pink Sheet
US Stem financial ratios help investors to determine whether USRM Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in USRM with respect to the benefits of owning US Stem security.